NEWS & EVENTS
Cresset Discovery accelerates METTL3 inhibitor design and optimization
In collaboration with EPICS Therapeutics, Cresset Discovery, a specialist in computational drug design, has developed an integrated modeling workflow to accelerate the discovery and optimization of a METTL3 inhibitor. By leveraging its expertise in molecular modeling and proprietary technology, Cresset enabled the rapid design and prioritization of novel compounds based on their three-dimensional shape and electrostatic properties.
Cresset’s computational design approach was combined with EPICS’ medicinal chemistry and experimental validation capabilities. This iterative process of in silico design and biological testing supported efficient hit identification and lead optimization, enabling progression toward a drug development candidate.
Dr Martin Slater, Director of Discovery and co-author on the paper said:
“We are delighted to have worked on this project with the talented team of scientists at Epics Therapeutics, demonstrating the power of combining computational methods with expert medicinal chemistry, providing significant efficiency gains through the hit identification and optimization phases of a drug discovery project.”
“We are grateful to Dr. Slater and his team at Cresset Discovery, UK for the exceptional modeling work conducted.”